公开(公告)号：US09757343B2

公开(公告)日：2017-09-12

申请号：US13062591

申请日：2008-09-24

申请人： Hans Bär ,  Thomas Fürst ,  Gerhard Renner ,  Michael Gottschalk

发明人： Hans Bär ,  Thomas Fürst ,  Gerhard Renner ,  Michael Gottschalk

IPC分类号： A61K9/50

CPC分类号： A61K9/5078

摘要： The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising a core, and an opioid, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250% by weight of a non-porous inert lubricant, 1 to 35% by weight of a neutral cellulosic compound and 1 to 25% by weight of an emulsifier, each calculated on dry weight of the polymer mixture.

公开(公告)号：US09730899B2

公开(公告)日：2017-08-15

申请号：US13256694

申请日：2009-03-18

申请人： Hans Bär ,  Thomas Fürst ,  Gerhard Renner ,  Michael Gottschalk

发明人： Hans Bär ,  Thomas Fürst ,  Gerhard Renner ,  Michael Gottschalk

IPC分类号： A61K9/52 ,  A61K9/14 ,  A61K31/485 ,  A61K9/50

CPC分类号： A61K9/5078

摘要： The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol, whereby the ethanol resistance conferring coating layer comprises at least 70% by weight of a mixture of a polymeric portion a) and an excipients portion b), with the polymeric portion a) is consisting of a water insoluble essentially neutral vinyl polymer or vinyl copolymer and the excipients portion b) is consisting of the excipients b1) 100 to 250% by weight of a non-porous inert lubricant, b2) 1 to 35% by weight of a cellulosic compound, b3) 0.1 to 25% by weight of an emulsifier and additionally or alternatively to b3), b4) 0.1 to 30% by weight of a plasticizer whereby the excipients of the excipients portion b) are each calculated on the dry weight of the polymer portion a).

公开(公告)号：US20110217383A1

公开(公告)日：2011-09-08

申请号：US13062591

申请日：2008-09-24

申请人： Hans Bär ,  Thomas Fürst ,  Gerhard Renner ,  Michael Gottschalk

发明人： Hans Bär ,  Thomas Fürst ,  Gerhard Renner ,  Michael Gottschalk

IPC分类号： A61K9/50 ,  A61K9/00 ,  A61P25/32 ,  A61P25/36 ,  A61K31/485 ,  A61K31/137 ,  A61K31/222 ,  A61K31/451 ,  A61K31/5377 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/439 ,  A61K31/24 ,  A61K31/4535 ,  A61K31/55 ,  A61K31/445 ,  A61P25/04 ,  B29C43/20

CPC分类号： A61K9/5078

摘要： The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising a core, and an opioid, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40 95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer, and ii) 5 60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250 % by weight of a non-porous inert lubricant, 1 to 35 % by weight of a neutral cellulosic compound and 1 to 25 % by weight of an emulsifier, each calculated on dry weight of the polymer mixture.

摘要翻译： 本发明涉及一种pH依赖性控释药物组合物，其包含核心和阿片样物质，其中所述核心至少涂覆一层涂层，以控制药物组合物的释放，其中所述涂层包含： i）40 95重量％，基于聚合物混合物的干重，至少一种水不溶性基本上中性的乙烯基聚合物，和ii）基于聚合物混合物的干重计，60重量％的至少一种 阴离子聚合物或共聚物，其不溶于低于pH 4.0的缓冲介质，并且至少可溶于pH 7.0至pH 8.0，其特征在于，所述涂层还包含110至250重量％的无孔惰性润滑剂 ，1至35重量％的中性纤维素化合物和1至25重量％的乳化剂，其各自以聚合物混合物的干重计算。

公开(公告)号：US20110229562A1

公开(公告)日：2011-09-22

申请号：US13120112

申请日：2008-09-24

申请人： Hans Bär ,  Thomas Fürst ,  Gerhard Renner ,  Michael Gottschalk

发明人： Hans Bär ,  Thomas Fürst ,  Gerhard Renner ,  Michael Gottschalk

IPC分类号： A61K9/48 ,  B29C43/02 ,  A61K9/00 ,  A61K9/36 ,  A61K9/14 ,  A61K31/138

CPC分类号： A61K9/5078

摘要： The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising at least one pharmaceutical active ingredient, with the exception of opioids, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer or copolymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250% by weight of a non-porous inert lubricant, 1 to 35% by weight of at least one neutral cellulosic compound and 1 to 25% by weight of at least one emulsifier, each calculated on dry weight of the polymer mixture.

摘要翻译： 本发明涉及pH依赖性控释药物组合物，其包含除阿片样物质以外的至少一种药物活性成分，其中核心至少涂覆一层涂层，以控制药物组合物的释放，其中涂层 至少一种不溶于水的基本上中性的乙烯基聚合物或共聚物，和ii）5-60重量％，基于干燥的聚合物混合物，i）40-95重量％，基于聚合物混合物的干重， 聚合物混合物的重量，至少一种阴离子聚合物或共聚物，其不溶于低于pH 4.0的缓冲介质中并且可溶于至少在7.0至8.0的范围内，其特征在于所述涂层还包含110至250 重量％的无孔惰性润滑剂，1至35重量％的至少一种中性纤维素化合物和1至25重量％的至少一种乳化剂，其各自以聚合物混合物的干重计算。

公开(公告)号：US10933024B2

公开(公告)日：2021-03-02

申请号：US13120112

申请日：2008-09-24

申请人： Hans Baer ,  Thomas Fuerst ,  Gerhard Renner ,  Michael Gottschalk

发明人： Hans Baer ,  Thomas Fuerst ,  Gerhard Renner ,  Michael Gottschalk

IPC分类号： A61K9/50 ,  A61P25/32 ,  A61P27/06 ,  A61P11/06 ,  A61P13/04

摘要： The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising at least one pharmaceutical active ingredient, with the exception of opioids, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer or copolymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250% by weight of a non-porous inert lubricant, 1 to 35% by weight of at least one neutral cellulosic compound and 1 to 25% by weight of at least one emulsifier, each calculated on dry weight of the polymer mixture.

公开(公告)号：US20120045506A1

公开(公告)日：2012-02-23

申请号：US13256694

申请日：2009-03-18

申请人： Hans Baer ,  Thomas Fuerst ,  Gerhard Renner ,  Michael Gottschalk

发明人： Hans Baer ,  Thomas Fuerst ,  Gerhard Renner ,  Michael Gottschalk

IPC分类号： A61K9/52 ,  A61K9/14 ,  A61K31/485 ,  B05D5/00 ,  A61K9/36 ,  A61P25/04 ,  B05D1/02 ,  A61K9/00 ,  A61K31/138

CPC分类号： A61K9/5078

摘要： The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol, whereby the ethanol resistance conferring coating layer comprises at least 70% by weight of a mixture of a polymeric portion a) and an excipients portion b), with the polymeric portion a) is consisting of a water insoluble essentially neutral vinyl polymer or vinyl copolymer and the excipients portion b) is consisting of the excipients b1) 100 to 250% by weight of a non-porous inert lubricant, b2) 1 to 35% by weight of a cellulosic compound, b3) 0.1 to 25% by weight of an emulsifier and additionally or alternatively to b3), b4) 0.1 to 30% by weight of a plasticizer whereby the excipients of the excipients portion b) are each calculated on the dry weight of the polymer portion a).

摘要翻译： 本发明涉及一种控释药物组合物，其包含核心，其包含药物活性成分，由此核心由赋予乙醇抗性的涂层涂覆，其具有赋予药物活性成分的释放特性以抵抗 乙醇的影响，其中赋予涂料的乙醇抗性包含至少70重量％的聚合物部分a）和赋形剂部分b）的混合物，聚合物部分a）由不溶于水的基本上为中性的乙烯基 聚合物或乙烯基共聚物和赋形剂部分b）由赋形剂b1）100-250重量％的无孔惰性润滑剂组成，b2）1至35重量％的纤维素化合物，b3）0.1至25重量％ 的b），b4）0.1〜30重量％的增塑剂，其中赋形剂部分b）的赋形剂各自计算 以聚合物部分a）的干重计。

公开(公告)号：US20110311631A1

公开(公告)日：2011-12-22

申请号：US13203760

申请日：2009-03-18

申请人： Hans Baer ,  Thomas Fuerst ,  Thomas Rupp ,  Gerhard Renner ,  Michael Gottschalk

发明人： Hans Baer ,  Thomas Fuerst ,  Thomas Rupp ,  Gerhard Renner ,  Michael Gottschalk

IPC分类号： A61K9/14 ,  A61K31/485 ,  B05D5/00 ,  A61K31/138 ,  A61K31/522 ,  A61K31/609 ,  A61K31/554

CPC分类号： A61K9/5078

摘要： The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol. The coating layer comprises a polymeric portion consisting of a water-insoluble neutral vinyl polymer or vinyl copolymer and an amino methacrylate copolymer and an excipients portion consisting of a lubricant, an emulsifier, a plasticizer and optionally a cellulosic compound.

摘要翻译： 本发明涉及一种控释药物组合物，其包含核心，其包含药物活性成分，由此核心由赋予乙醇抗性的涂层涂覆，其具有赋予药物活性成分的释放特性以抵抗 乙醇的影响。 涂层包括由不溶于水的中性乙烯基聚合物或乙烯基共聚物和氨基甲基丙烯酸酯共聚物组成的聚合物部分和由润滑剂，乳化剂，增塑剂和任选的纤维素化合物组成的赋形剂部分。

公开(公告)号：US20050167937A1

公开(公告)日：2005-08-04

申请号：US10770601

申请日：2004-02-04

申请人： Michael Gottschalk

发明人： Michael Gottschalk

IPC分类号： B60B35/06 ,  B60B35/08 ,  B60G9/00 ,  B60G11/27 ,  B60G11/28 ,  B62D61/12

CPC分类号： B60G11/28 ,  B60B35/06 ,  B60G9/00 ,  B60G2200/314 ,  B60G2204/126 ,  B60G2204/1482 ,  B60G2204/43 ,  B60G2206/30 ,  B60G2206/8207

摘要： A multi-piece axle employing assembly hardware for forming a rigid axle structure which, in addition, connects the multi-piece axle to a suspension, thereby eliminating conventional axle seats. More specifically, a multi-piece axle having dual function hardware for simultaneously assembling the axle into a single rigid member as well as assembling a suspension portion thereto.

摘要翻译： 一种多片轴，其使用用于形成刚性轴结构的组装硬件，此外还将多片轴连接到悬架，从而消除常规轴座。 更具体地说，一种具有双功能硬件的多片轴，用于同时将轴组装成单个刚性构件以及将悬架部分组装在其上。

公开(公告)号：US06228632B1

公开(公告)日：2001-05-08

申请号：US09011540

申请日：1998-04-20

申请人： Erwin Schuster ,  Bruno Sproessler ,  Kornelia Titze ,  Michael Gottschalk ,  Nguyen Quoc Khanh ,  Sabine Wolf ,  Hermann Plainer

发明人： Erwin Schuster ,  Bruno Sproessler ,  Kornelia Titze ,  Michael Gottschalk ,  Nguyen Quoc Khanh ,  Sabine Wolf ,  Hermann Plainer

IPC分类号： C12N948

CPC分类号： C12N9/48

摘要： This invention relates to a recombinant deoxyribonucleic acid (DNA) which can be isolated from Aspergillus soyae, characterised in that it codes for a leucine aminopeptidase (LAP) and comprises a nucleotide sequence corresponding to the nucleotide sequence given in SEQ ID NO: 1 for the mature LAP or to a nucleotide sequence derived therefrom which hybridises under stringent conditions with the nucleotide sequence given in SEQ ID NO: 1 for the mature LAP. The invention further relates to vectors and transformed host organisms, and also relates to methods of producing LAP. Enzyme products for the production of protein hydrolysates, as well as protein hydrolysates which are produced correspondingly, also form part of the invention.

摘要翻译： 本发明涉及可从大豆粉中分离的重组脱氧核糖核酸（DNA），其特征在于其编码亮氨酸氨基肽酶（LAP），其包含对应于SEQ ID NO：1中给出的核苷酸序列的核苷酸序列，用于 成熟LAP或衍生自其的核苷酸序列，其在严格条件下与成熟LAP的SEQ ID NO：1中给出的核苷酸序列杂交。 本发明进一步涉及载体和转化的宿主生物，并且还涉及产生LAP的方法。 用于生产蛋白质水解产物的酶产物以及相应生产的蛋白质水解产物也构成本发明的一部分。

公开(公告)号：US09050256B2

公开(公告)日：2015-06-09

申请号：US13390353

申请日：2010-08-30

申请人： Benedikt Hartwig ,  Norbert Windhab ,  Melanie Liefke ,  Juan Tome Alcalde ,  Michael Damm ,  Rosario Lizio ,  Michael Gottschalk ,  Angela Olf ,  Christian Meier ,  Andreas Gryczke

发明人： Benedikt Hartwig ,  Norbert Windhab ,  Melanie Liefke ,  Juan Tome Alcalde ,  Michael Damm ,  Rosario Lizio ,  Michael Gottschalk ,  Angela Olf ,  Christian Meier ,  Andreas Gryczke

IPC分类号： A61B5/055 ,  A61K9/20 ,  A61K9/28 ,  A61K9/48 ,  A61K9/50 ,  A61K9/00

CPC分类号： A61K9/2072 ,  A61K9/0009 ,  A61K9/0053 ,  A61K9/2095 ,  A61K9/2813 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/4808 ,  A61K9/4816 ,  A61K9/4833 ,  A61K9/4883 ,  A61K9/5094

摘要： The invention relates to an oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles, wherein the dosage form has an at least two phase composition, wherein the phases can dissolve in the body after oral administration due to their formulation and the magnetizable particles are bound in formulation auxiliary substances and are present in a magnetized state, wherein the magnetized particles are present in at least two phases of the dosage form and generate magnetic fields, wherein these phases dissolve at different times in the body after oral administration, and wherein the magnetic field strength with respect to time, position and movement in the body is acquired using a detection system and can be evaluated using a computer-based evaluation system.

摘要翻译： 本发明涉及口服剂型，其包含至少一种生物活性剂，制剂辅助物质和可磁化颗粒，其中所述剂型具有至少两相组合物，其中所述相可以在口服给药后溶于体内，因为它们 制剂和可磁化颗粒结合在制剂辅助物质中并以磁化状态存在，其中磁化颗粒存在于剂型的至少两个相中并产生磁场，其中这些相在体内不同时间溶解在体内 并且其中使用检测系统获取相对于身体中的时间，位置和运动的磁场强度，并且可以使用基于计算机的评估系统进行评估。